A CASE OF MONONEURITIS MULTIPLEX WITH GIANT CELL ARTERITIS
Keywords:
Giant cell arteritis, Mononeuritis multiplex, Polymyalgia rheumaticaAbstract
Giant cell arteritis (GCA) is a serious and difficult to diagnose inflammatory vasculopathy that involves large and medium-sized arteries. While the disease may present with blindness or other signs of extracranial vasculitis, symptoms referable to the peripheral nervous system has been reported in 14 % of the patient with GCA. Temporal artery biopsy is the gold standard test for the diagnosis of GCA, but may not be necessary in patients with typical disease features accompanied by characteristic ultrasound or MRI findings revealing wall thickening caused by inflammation (specificity 78%-100% for ultrasound and 73%-97% for MRI), as in our patient. A temporal artery biopsy is the gold standard test for the diagnosis of GCA, but it may not be required in patients with typical disease features accompanied by characteristic ultrasound or MRI findings. We report a case of association of the Mononeuritis multiplex with GCA.
Timely diagnosis and initiation of therapy is important because of the risk of vascular ischemic complications due to GCA and subsequent severe disability with serious social and economic consequences.
References
Bienvenu B, Ly KH, Lambert M, et al. (2016). Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 37:154
Bond, M., Al. omelleri et al. (2022). Looking ahead: giant-cell arteritis in 10 years time. SAGE journals. Therapeutic Advances in Musculoskeletal Disease. Vol. 14: 1-20, https://journals.sagepub.com/doi/pdf
Clinical Key. (2021). Giant cell artreritis, Elsevier Point of care. Updated 24 mar
Crowson CS, Matteson EL, Myasoedova E, et al. (2011).The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 63:633
Dasgupta B, Borg FA, Hassan N, et al. (2010). BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 49:1594
Duhaut P et al. (1999). Giant cell artreritis, polymialgia rheumatic and viral hypotheses: a multicenter, prospective case control study. J Rheumatology. 26:361-9
Gerald DM et al. (2019). Minimally invasive procedures. In: Hochberg MC et al, eds: Rheumatology, 7th ed. Elsevier:347-51
Gonzalez-Gay MA. (2004). Giant cell artreritis and polymialgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum. 33(5): 289-93
Guerava M et al. (2018). Recent advances in giant cell artreritis. Curr Rheumatology Rep. 20(5):25
Mukhtyar C, Guillevin L, Cid MC, et al. (2009). EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 68:318
Prior JA et al. (2017). Diagnostic delay for giant cell artreritis – a systemic review and meta-analysis. BMC Med. 15 (1):120
Puppo C, Massollo M et all. (2014). Giant cell artreritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. Biomed Res Int. 57 (4):248
Stone JH et al. (2017). Trial of tocilizumab in giant cell artreritis. N Engl J Med.377 (4):317-28
Younger DS. (2019). Giant cell artreritis, Neurol Clin. 37 (2):335-44